Pharma - Revision history

74.98.206.195: /* Johnson & Johnson */

2018-10-16T17:29:35Z

Johnson & Johnson

Admin: Dar/Etter report added

2015-10-17T02:06:24Z

Dar/Etter report added

Mamoune: /* The pharmaceutical interests supporting Tobacco Control */

2012-09-02T01:17:33Z

The pharmaceutical interests supporting Tobacco Control

Cantiloper: Slight phrasing change in Mamoune's addition.

2012-09-01T19:49:58Z

Slight phrasing change in Mamoune's addition.

Admin: /* GlaxoSmithKline */ Benelux

2012-09-01T01:11:29Z

GlaxoSmithKline: Benelux

Admin: /* Johnson & Johnson */ Added Nicorette

2012-09-01T01:10:11Z

Johnson & Johnson: Added Nicorette

Admin: /* Pfizer */

2012-09-01T01:03:50Z

Pfizer

Admin: /* Pfizer */

2012-09-01T00:53:53Z

Pfizer

Admin: SEO: BP

2012-09-01T00:51:46Z

SEO: BP

Mamoune: /* The pharmaceutical interests supporting Tobacco Control */

2012-08-31T01:11:37Z

The pharmaceutical interests supporting Tobacco Control

@@ Line 55: / Line 55: @@
 ==Company Listing==
 ===Johnson &amp; Johnson===
-:Under the banner of its subsidiary, McNeil Consumer Products, J&amp;J markets the Nicotrol nicotine patch and nicotine inhaler. The Robert Wood Johnson Foundation is the biggest single shareholder in J&amp;J and began its massive funding of tobacco control in the U.S. in 1991, the same year the FDA approved the nicotine patch as a prescription drug. Pharmacia reacquired the rights to market the Nicotrol Inhaler in North America from J&amp;J's McNeil in July 2000.
+:Under the banner of its subsidiary, McNeil Consumer Products, J&amp;J markets the Nicotrol nicotine patch and nicotine inhaler. The Robert Wood Johnson Foundation is a big shareholder in J&amp;J and began its massive funding of tobacco control in the U.S. in 1991, the same year the FDA approved the nicotine patch as a prescription drug. Pharmacia reacquired the rights to market the Nicotrol Inhaler in North America from J&amp;J's McNeil in July 2000.
 ===GlaxoSmithKline===
 :Pharmaceutical giants Glaxo Wellcome and SmithKline Beecham merged on December 27, 2000, making the new company the world's biggest drugs group by sales. Glaxo Wellcome markets Zyban (buproprion) and SKB markets Nicoderm CQ nicotine patch and Nicorette gum. One of the major holdups in getting FTC approval for the merger was that both companies sold smoking cessation products, but even though these cessation products accounted for less than 4% of SK's sales, neither company was willing for them to be sold to another pharmaceutical company to facilitate the merger. SK was also investigated by a congressional committee for overpricing of cancer treatments. SK infuriated the committee by refusing to hand over information about Kytril, its anti-nausea drug for chemotheraphy patients. ("Federal smoke delays merger," Andrew Clark, ''The Guardian'', October 10, 2000).

@@ Line 23: / Line 23: @@
 In fact in most cases, the success rate was higher if '''no''' NRT was used.
+Additionally, a study by Reuven Dar and Jean-Jacques Etter showed that commonly used placebo tests that test the effect of NRT products, carried out by the pharmaceutical nicotine producers, are defective and overestimate the effect of those products. <ref>[http://whyquit.com/studies/2005_Dar_NRT_Placebo_Effect.pdf Assigned Versus Perceived Placebo Effects in Nicotine Replacement Therapy for Smoking Reduction in Swiss Smokers]</ref>
 Gregory N. Connolly, professor of the Practice of Public Health, Director, Center for Global Tobacco Control recently published a study <ref>[http://tobaccocontrol.bmj.com/content/early/2012/01/10/tobaccocontrol-2011-050129.abstract A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation]</ref> that he co-authored that came to the following conclusion
 <blockquote>This study finds that persons who have quit smoking relapsed at equivalent rates, whether or not they used NRT to help them in their quit attempts. Cessation medication policy should be made in the larger context of public health, and increasing individual treatment coverage should not be at the expense of population evidence-based programmes and policies.</blockquote>

@@ Line 43: / Line 43: @@
 the move to NRT as the only way to combat this addiction is seen as normative. Unassisted smoking cessation is seen as ineffective since smokers’ conﬁdence in their ability to succeed is undermined by their belief that they are addicted.<ref>[http://www.democracyinstitute.org/LiteratureRetrieve.aspx?ID=108974&A=SearchResult&SearchID=4783725&ObjectID=108974&ObjectType=6 PRESCRIPTION FOR CONFLICT: WHY THE ALLIANCE BETWEEN THE PHARMACEUTICAL INDUSTRY AND THE ANTI-TOBACCO MOVEMENT IS NOT IN THE BEST INTERESTS OF SMOKERS]</ref></blockquote>
-Israeli studies conducted by Dr. Reuven Dar conclude that nicotine is not addictive as physiological addictions are usually defined. Nicotine does have a physiological role in increasing cognitive abilities but it's not an addictive substance -- like heroin for example -- which creates pronounced biological withdrawal symptoms.  Dr. Dar believes that understanding smoking as a habit, as opposed to an addiction, will put the emphasis on psychological and behavioral aspects when helping smokers quit. This is less than likely to happen, because with the billions of profits Big Pharma risks to lose if the nicotine addiction theory is  disproved by an ever increasing number of researchers, it will persistently defend it anyway: they will always find scientists and tobacco control advocates all too eager to perpetuate a fallacy for money.  ''These findings might not be popular with advocates of the nicotine addiction theory, because they undermine the physiological role of nicotine and emphasize mind over matter when it comes to smoking '' Dr. Dar sharply opines. <ref>[http://www.sciencedaily.com/releases/2010/07/100713144920.htm Smoking Mind Over Smoking Matter: Surprising New Study Shows Cigarette Cravings Result from Habit, Not Addiction]</ref>
+Israeli studies conducted by Dr. Reuven Dar conclude that nicotine is not addictive as physiological addictions are usually defined. Nicotine does have a physiological role in increasing cognitive abilities but it's not an addictive substance -- like heroin for example -- which creates biological withdrawal symptoms.  Dr. Dar believes that understanding smoking as a habit, as opposed to an addiction, will put the emphasis on psychological and behavioral aspects when helping smokers quit. This is less than likely to happen, because with the billions of profits Big Pharma risks to lose if the nicotine addiction theory is  disproved by an ever increasing number of researchers, it will persistently defend it anyway: they will always find scientists and tobacco control advocates all too eager to perpetuate a fallacy for money.  ''These findings might not be popular with advocates of the nicotine addiction theory, because they undermine the physiological role of nicotine and emphasize mind over matter when it comes to smoking '' Dr. Dar sharply opines. <ref>[http://www.sciencedaily.com/releases/2010/07/100713144920.htm Smoking Mind Over Smoking Matter: Surprising New Study Shows Cigarette Cravings Result from Habit, Not Addiction]</ref>
 Funding Tobacco Control organizations, astroturf groups and bans is not all the pharmaceutical industry does to boost its profits. It also practices a devious way to advertise cessation drugs (without even naming them) in the form of infomercials that mislead the viewer into thinking that they are public service  messages.  A typical example can be found here: [http://www.youtube.com/watch?v=j8orUjJXkKo New Advertising Trend: Fake "Public Service" Ads ] .  The following quit ''campaign'' [http://quit-smoking-canada.ca/en/home/ Quit Smoking Canada ] carries a tiny mention at the bottom ''This campaign is brought to you by one of canada’s leading research-based pharmaceutical companies '' without which the reader would have never known that it was Big Pharma funded.

@@ Line 1: / Line 1: @@
 == The pharmaceutical interests supporting Tobacco Control ==
 Pharmaceutical companies sponsor conferences of TC groups, studies that attempt to prove environmental tobacco smoke (ETS) is deadly and (financially) support the WHO/FCTC in their fight against smokers.
@@ Line 30: / Line 28: @@
 <blockquote>This study finds that persons who have quit smoking relapsed at equivalent rates, whether or not they used NRT to help them in their quit attempts. Cessation medication policy should be made in the larger context of public health, and increasing individual treatment coverage should not be at the expense of population evidence-based programmes and policies.</blockquote>
-Please note that letters disagreeing with this study were all submitted by researchers who had ties to the pharmaceutical industry.<ref>[http://tobaccocontrol.bmj.com/content/early/2012/01/10/tobaccocontrol-2011-050129.abstract/reply#tobaccocontrol_el_3882 Replies to A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation ]</ref> What is intriguing about this study is that it was completed in 2006 yet it was only published in January 2012.  Could Professor Connolly's resignation <ref>[http://online.wsj.com/article/SB10001424052748704405704576064000800551720.html FDA Tobacco Adviser Resigns ]</ref> from the FDA tobacco-advisory committee have anything to do with it? Could his support <ref>[http://axcessnews.com/index.php/articles/show/id/21667 Harvard Prof's Interview Lends Impetus to 22nd Century Group's Very Low Nicotine Tobacco ]</ref>  of a pharmaceutical smoked cigarette (that would most probably compete with nicotine replacement treatment) have anything to do with the delayed publication of this study?  Whatever the reasons, it is quite strange that in the ''publish or perish'' world of epidemiology,<ref>[http://www.timeshighereducation.co.uk/story.asp?storycode=411323 'Publish or perish' culture distorting research results]</ref> research would be published with a 6-year delay
+Please note that letters disagreeing with this study were all submitted by researchers who had ties to the pharmaceutical industry.<ref>[http://tobaccocontrol.bmj.com/content/early/2012/01/10/tobaccocontrol-2011-050129.abstract/reply#tobaccocontrol_el_3882 Replies to A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation ]</ref> What is intriguing about this study is that it was completed in 2006 yet it was only published in January 2012.  Could Professor Connolly's resignation <ref>[http://online.wsj.com/article/SB10001424052748704405704576064000800551720.html FDA Tobacco Adviser Resigns ]</ref> from the FDA tobacco-advisory committee have anything to do with it? Could his support <ref>[http://axcessnews.com/index.php/articles/show/id/21667 Harvard Prof's Interview Lends Impetus to 22nd Century Group's Very Low Nicotine Tobacco ]</ref>  of a pharmaceutical smoked cigarette (that would most probably compete with nicotine replacement treatment) have anything to do with the delayed publication of this study?  Whatever the reasons, it is quite strange that in the ''publish or perish'' world of epidemiology,<ref>[http://www.timeshighereducation.co.uk/story.asp?storycode=411323 'Publish or perish' culture distorting research results]</ref> research would be published after a 6-year delay
 But when even the father of the universally known and utilized ''nicotine dependence test'', Karl Fagerström,  has a change of heart  and now concedes that nicotine is not the only reason people smoke, is it any wonder nicotine replacement therapy is virtually useless? <ref>[http://www.formindep.org/Fagerstrom-Finds-His-Way-To.html Fagerström Finds His Way To Damascus]</ref>
@@ Line 45: / Line 43: @@
 the move to NRT as the only way to combat this addiction is seen as normative. Unassisted smoking cessation is seen as ineffective since smokers’ conﬁdence in their ability to succeed is undermined by their belief that they are addicted.<ref>[http://www.democracyinstitute.org/LiteratureRetrieve.aspx?ID=108974&A=SearchResult&SearchID=4783725&ObjectID=108974&ObjectType=6 PRESCRIPTION FOR CONFLICT: WHY THE ALLIANCE BETWEEN THE PHARMACEUTICAL INDUSTRY AND THE ANTI-TOBACCO MOVEMENT IS NOT IN THE BEST INTERESTS OF SMOKERS]</ref></blockquote>
-Israeli studies conducted by Dr. Reuven Dar conclude that nicotine is not addictive as physiological addictions are usually defined. Nicotine does have a physiological role in increasing cognitive abilities but it's not an addictive substance like heroin for example, which creates biological withdrawal symptoms.  Dr. Dar believes that understanding smoking as a habit, as opposed to an addiction, will put the emphasis on psychological and behavioral aspects when helping smokers quit. This is less than likely to happen, because with the billions of profits Big Pharma risks to lose if the nicotine addiction theory is  disproved by an ever increasing number of researchers, it will persistently continue to defend it anyway as they will always find scientists and tobacco control advocates all too eager to perpetuate a fallacy for money.  ''These findings might not be popular with advocates of the nicotine addiction theory, because they undermine the physiological role of nicotine and emphasize mind over matter when it comes to smoking '' Dr. Dar astutely opines. <ref>[http://www.sciencedaily.com/releases/2010/07/100713144920.htm Smoking Mind Over Smoking Matter: Surprising New Study Shows Cigarette Cravings Result from Habit, Not Addiction]</ref>
+Israeli studies conducted by Dr. Reuven Dar conclude that nicotine is not addictive as physiological addictions are usually defined. Nicotine does have a physiological role in increasing cognitive abilities but it's not an addictive substance -- like heroin for example -- which creates pronounced biological withdrawal symptoms.  Dr. Dar believes that understanding smoking as a habit, as opposed to an addiction, will put the emphasis on psychological and behavioral aspects when helping smokers quit. This is less than likely to happen, because with the billions of profits Big Pharma risks to lose if the nicotine addiction theory is  disproved by an ever increasing number of researchers, it will persistently defend it anyway: they will always find scientists and tobacco control advocates all too eager to perpetuate a fallacy for money.  ''These findings might not be popular with advocates of the nicotine addiction theory, because they undermine the physiological role of nicotine and emphasize mind over matter when it comes to smoking '' Dr. Dar sharply opines. <ref>[http://www.sciencedaily.com/releases/2010/07/100713144920.htm Smoking Mind Over Smoking Matter: Surprising New Study Shows Cigarette Cravings Result from Habit, Not Addiction]</ref>
 Funding Tobacco Control organizations, astroturf groups and bans is not all the pharmaceutical industry does to boost its profits. It also practices a devious way to advertise cessation drugs (without even naming them) in the form of infomercials that mislead the viewer into thinking that they are public service  messages.  A typical example can be found here: [http://www.youtube.com/watch?v=j8orUjJXkKo New Advertising Trend: Fake "Public Service" Ads ] .  The following quit ''campaign'' [http://quit-smoking-canada.ca/en/home/ Quit Smoking Canada ] carries a tiny mention at the bottom ''This campaign is brought to you by one of canada’s leading research-based pharmaceutical companies '' without which the reader would have never known that it was Big Pharma funded.
@@ Line 56: / Line 54: @@
 ==Company Listing==
 ===Johnson &amp; Johnson===
-:Under the banner of its subsidiary, McNeil Consumer Products, J&amp;J markets the Nicotrol/Nicorette nicotine patch and nicotine inhaler. The Robert Wood Johnson Foundation is the biggest single shareholder in J&amp;J and began its massive funding of tobacco control in the U.S. in 1991, the same year the FDA approved the nicotine patch as a prescription drug. Pharmacia reacquired the rights to market the Nicotrol Inhaler in North America from J&amp;J's McNeil in July 2000.
+:Under the banner of its subsidiary, McNeil Consumer Products, J&amp;J markets the Nicotrol nicotine patch and nicotine inhaler. The Robert Wood Johnson Foundation is the biggest single shareholder in J&amp;J and began its massive funding of tobacco control in the U.S. in 1991, the same year the FDA approved the nicotine patch as a prescription drug. Pharmacia reacquired the rights to market the Nicotrol Inhaler in North America from J&amp;J's McNeil in July 2000.
 ===GlaxoSmithKline===
 :Pharmaceutical giants Glaxo Wellcome and SmithKline Beecham merged on December 27, 2000, making the new company the world's biggest drugs group by sales. Glaxo Wellcome markets Zyban (buproprion) and SKB markets Nicoderm CQ nicotine patch and Nicorette gum. One of the major holdups in getting FTC approval for the merger was that both companies sold smoking cessation products, but even though these cessation products accounted for less than 4% of SK's sales, neither company was willing for them to be sold to another pharmaceutical company to facilitate the merger. SK was also investigated by a congressional committee for overpricing of cancer treatments. SK infuriated the committee by refusing to hand over information about Kytril, its anti-nausea drug for chemotheraphy patients. ("Federal smoke delays merger," Andrew Clark, ''The Guardian'', October 10, 2000).
-:In 1999, SmithKline Beecham Consumer Healthcare's combined U.S. sales of Nicorette and NicoDerm CQ reached $570 million. The company also markets its nicotine patch under the trade name "NiQuitin CQ" in BeNeLux, France, Denmark, Mexico and Brazil and under "Nicabate" in Australia and New Zealand, where it was the number one smoking cessation product in 1999 ([http://archive.tobacco.org/resources/rendezvous/ashburn.html Philippe Boucher's Rendez-vous with ... Leslie A. Ashburn, Communications Supervisor for GlaxoSmithKline, January 29, 2001]).
+:In 1999, SmithKline Beecham Consumer Healthcare's combined U.S. sales of Nicorette and NicoDerm CQ reached $570 million. The company also markets its nicotine patch under the trade name "NiQuitin CQ" in Belgium, France, Denmark, Mexico and Brazil and under "Nicabate" in Australia and New Zealand, where it was the number one smoking cessation product in 1999 ([http://archive.tobacco.org/resources/rendezvous/ashburn.html Philippe Boucher's Rendez-vous with ... Leslie A. Ashburn, Communications Supervisor for GlaxoSmithKline, January 29, 2001]).
 ===Pharmacia===
@@ Line 80: / Line 77: @@
 :"Novartis Pharma To Launch Nicotine Patches in Japan," ''NewsEdge'', May 11, 1999. "Although the patches are available over-the-counter in 29 countries, they will require a doctor's prescription in Japan and will not be covered by insurance."
 ===Pfizer===
-:Last but not least: Discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world's best known consumer products. Pfizer had global revenues of $29.6 billion in 2000. In 2000 Pfizer took over Warner-Lambert. Pfizer is developing a new agent for smoking cessation, currently known as CP-526,555, "that relieves both cravings and withdrawal symptoms and blocks the reinforcing effect of smoking" ("Pfizer to Advance Industry Leadership Through the Best People, Products And Pipeline, Steere Tells Shareholders," Company Press Release, April 26, 2001).
+:Discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world's best known consumer products. Pfizer had global revenues of $29.6 billion in 2000. In 2000 Pfizer took over Warner-Lambert. Pfizer is developing a new agent for smoking cessation, currently known as CP-526,555, "that relieves both cravings and withdrawal symptoms and blocks the reinforcing effect of smoking" ("Pfizer to Advance Industry Leadership Through the Best People, Products And Pipeline, Steere Tells Shareholders," Company Press Release, April 26, 2001).
 :Main sponsor for TC conferences and main supporter of the FCTC.

@@ Line 60: / Line 60: @@
 ===GlaxoSmithKline===
 :Pharmaceutical giants Glaxo Wellcome and SmithKline Beecham merged on December 27, 2000, making the new company the world's biggest drugs group by sales. Glaxo Wellcome markets Zyban (buproprion) and SKB markets Nicoderm CQ nicotine patch and Nicorette gum. One of the major holdups in getting FTC approval for the merger was that both companies sold smoking cessation products, but even though these cessation products accounted for less than 4% of SK's sales, neither company was willing for them to be sold to another pharmaceutical company to facilitate the merger. SK was also investigated by a congressional committee for overpricing of cancer treatments. SK infuriated the committee by refusing to hand over information about Kytril, its anti-nausea drug for chemotheraphy patients. ("Federal smoke delays merger," Andrew Clark, ''The Guardian'', October 10, 2000).
-:In 1999, SmithKline Beecham Consumer Healthcare's combined U.S. sales of Nicorette and NicoDerm CQ reached $570 million. The company also markets its nicotine patch under the trade name "NiQuitin CQ" in Belgium, France, Denmark, Mexico and Brazil and under "Nicabate" in Australia and New Zealand, where it was the number one smoking cessation product in 1999 ([http://archive.tobacco.org/resources/rendezvous/ashburn.html Philippe Boucher's Rendez-vous with ... Leslie A. Ashburn, Communications Supervisor for GlaxoSmithKline, January 29, 2001]).
+:In 1999, SmithKline Beecham Consumer Healthcare's combined U.S. sales of Nicorette and NicoDerm CQ reached $570 million. The company also markets its nicotine patch under the trade name "NiQuitin CQ" in BeNeLux, France, Denmark, Mexico and Brazil and under "Nicabate" in Australia and New Zealand, where it was the number one smoking cessation product in 1999 ([http://archive.tobacco.org/resources/rendezvous/ashburn.html Philippe Boucher's Rendez-vous with ... Leslie A. Ashburn, Communications Supervisor for GlaxoSmithKline, January 29, 2001]).
 ===Pharmacia===

← Older revision		Revision as of 00:51, 1 September 2012
Line 1:		Line 1:
		+	<metakey>tobacco,control,industry,tobacco control,tobacco control industry,junk-science,science,ETS,second hand smoke,advocates,interests,competing,tobacco tactics,pharmaceutical,Pfizer,Glaxo,Big Pharma</metakey>
		+	<metadesc>A worldwide overview of pharmaceutical industries benefiting from Tobacco Control. Pharmaceutical companies sponsor conferences of TC groups, studies that attempt to prove environmental tobacco smoke (ETS) is deadly and (financially) support the WHO/FCTC in their fight against smokers.</metadesc>
	== The pharmaceutical interests supporting Tobacco Control ==		== The pharmaceutical interests supporting Tobacco Control ==
	Pharmaceutical companies sponsor conferences of TC groups, studies that attempt to prove environmental tobacco smoke (ETS) is deadly and (financially) support the WHO/FCTC in their fight against smokers.		Pharmaceutical companies sponsor conferences of TC groups, studies that attempt to prove environmental tobacco smoke (ETS) is deadly and (financially) support the WHO/FCTC in their fight against smokers.